Topical Finasteride for Hair Loss
Topical finasteride is finasteride applied directly to the scalp in an effort to reduce dihydrotestosterone, or DHT, within susceptible hair follicles while limiting systemic exposure compared with oral finasteride.
Finasteride is a prescription 5 alpha reductase inhibitor. It reduces the conversion of testosterone into DHT, the androgen that plays a central role in follicular miniaturization in genetically susceptible men with androgenetic alopecia.
The goal of topical treatment is not to create a different drug. It is to deliver finasteride differently.
A properly formulated topical finasteride product can produce meaningful hair growth while exposing the body to substantially less circulating finasteride than oral treatment.
That does not mean topical finasteride remains entirely within the scalp.
Finasteride applied to the skin can enter the bloodstream, can reduce serum DHT and can potentially produce systemic adverse effects.
There is currently no FDA approved topical finasteride product in the United States. Most topical finasteride prescribed in the United States is compounded.
Standardized topical finasteride sprays have, however, been authorized in multiple European countries since 2020, and topical finasteride now has substantial randomized clinical trial evidence supporting its efficacy in men with androgenetic alopecia.
How Finasteride Works
Testosterone can be converted into DHT by enzymes known as 5 alpha reductases.
Finasteride preferentially inhibits type 2 5 alpha reductase, an important source of DHT within susceptible scalp hair follicles and the prostate.
Men with androgenetic alopecia do not necessarily have unusually high levels of testosterone or DHT.
The underlying problem is the inherited sensitivity of certain scalp follicles to androgen signaling.
Over time, susceptible follicles gradually miniaturize. Their growth phase becomes shorter, the diameter of the hair decreases and the follicle eventually produces hair that is too fine and short to provide meaningful coverage.
Reducing DHT can slow or interrupt that process.
Finasteride is therefore primarily a preservation treatment, although miniaturized follicles can also increase in diameter and produce visible regrowth.
Why Was Topical Finasteride Developed?
Oral finasteride is highly effective and has decades of clinical evidence behind it.
But oral administration exposes the entire body to the drug and substantially reduces circulating DHT.
Topical finasteride was developed to answer an obvious question:
Can enough finasteride be delivered to the scalp to inhibit DHT within susceptible follicles while reducing systemic drug exposure?
Modern pharmacokinetic studies indicate that this can be accomplished with certain formulations.
The important qualification is with certain formulations.
Systemic exposure depends on concentration, application volume, treatment area, vehicle and frequency.
A topical formulation that produces excellent results and limited systemic exposure in a clinical trial cannot automatically be considered interchangeable with every compounded topical finasteride product.
Is Topical Finasteride FDA Approved?
No.
There is currently no FDA approved topical finasteride product in the United States, either alone or in combination with minoxidil.
Finasteride tablets are FDA approved for specific indications. Finasteride 1 mg is approved for male pattern hair loss, while finasteride 5 mg is approved for benign prostatic hyperplasia.
Topical finasteride prescribed in the United States is generally compounded.
Compounded medications can serve legitimate medical needs, but compounded drugs are not FDA approved and do not undergo FDA premarket evaluation for safety, effectiveness and quality in the same way as approved medications.
The FDA specifically reiterated this distinction in its 2025 warning concerning compounded topical finasteride.
Is Topical Finasteride Approved Anywhere?
Yes.
A standardized finasteride cutaneous spray containing 2.275 mg per mL has been authorized in a number of European countries since 2020 for the treatment of early male androgenetic alopecia.
European regulatory records list authorized topical products in countries including Belgium, France, Germany, Italy, Portugal and Spain.
The authorized indication generally applies to adult men approximately 18 to 41 years of age with mild to moderate male pattern hair loss.
That age range and disease stage are worth recognizing. The major European Phase III program also studied relatively young men with mild to moderate androgenetic alopecia.
The clinical trials therefore should not automatically be interpreted as proving identical outcomes in considerably older men or patients with very advanced hair loss.
The existence of an authorized European spray also does not mean an American compounded product with a similar percentage has the same formulation, application dose, absorption or safety profile.
Does Topical Finasteride Actually Work?
Yes.
The strongest evidence comes from a large Phase III randomized controlled trial of a standardized topical finasteride spray.
The study randomized 458 men with androgenetic alopecia to topical finasteride, placebo or oral finasteride and followed them for 24 weeks.
At week 24, the adjusted increase in target area hair count was approximately:
20.2 hairs with topical finasteride
6.7 hairs with placebo
21.1 hairs with oral finasteride
Topical finasteride significantly outperformed placebo.
Its average hair count improvement was numerically very similar to oral finasteride during the 24 week trial.
That wording matters.
The trial demonstrates strong efficacy for the particular standardized topical formulation studied. It does not establish that every compounded topical finasteride preparation is equivalent to oral finasteride or that six month results prove equivalent efficacy over five or ten years.
A Second Phase III Trial
A second large Phase III trial provides additional evidence.
The study enrolled 270 Chinese men at 16 clinical sites and randomized them to topical finasteride spray or placebo once daily for 24 weeks. Two hundred fifty one participants completed treatment.
Topical finasteride produced significantly greater improvement in target area hair count at week 24, greater improvement in terminal hair counts and greater investigator assessed vertex hair growth compared with placebo.
The treatment was generally well tolerated.
The study was published online in 2025 and appears in the 2026 volume of the Chinese Medical Journal.
This trial is important because it demonstrates efficacy in another large population rather than relying entirely on the original European Phase III study.
What Do We Know About Topical Finasteride Beyond Six Months?
Randomized Phase III evidence remains centered primarily around 24 weeks, but we now have useful one year real world evidence.
A 2026 retrospective study from the University of Turin followed 123 men using topical finasteride 0.25 percent as monotherapy for 52 weeks.
Hair number increased significantly in both the vertex and temporal regions. Hair shaft thickness and the ratio of terminal to vellus hairs also improved.
Mild temporary local irritation was reported in 7.3 percent of patients. No sexual or mood related systemic adverse effects were reported during the study.
A separate 2026 retrospective study followed 146 men for 52 weeks.
Target area hair counts increased significantly in both the vertex and frontotemporal areas. The average increase was approximately 22.7 hairs per square centimeter in the vertex and 32.3 hairs per square centimeter in the frontotemporal region. Hair width and terminal to vellus ratios also improved.
Mild temporary local irritation occurred in 6.2 percent of patients, and no systemic adverse effects were reported.
These studies are encouraging, but they are observational studies without randomized placebo groups.
One also excluded patients with previous sexual, mood related or gynecomastia related disorders. The absence of systemic adverse effects in that selected population therefore should not be interpreted as proving that systemic adverse effects cannot occur.
The one year data strengthen the evidence for durability of response, but they do not replace long term randomized safety studies.
Is Topical Finasteride as Effective as Oral Finasteride?
The best answer is that a standardized topical formulation produced average short term hair count improvement very similar to oral finasteride in a major controlled trial.
That is not the same as saying the two approaches have been proven identical.
In the European Phase III study, topical finasteride produced an adjusted increase of 20.2 target area hairs at 24 weeks compared with 21.1 with oral finasteride.
Oral finasteride, however, has decades of clinical experience and long term studies extending far beyond the current controlled topical evidence.
Topical finasteride now has strong short term randomized evidence and increasingly useful one year observational data.
It still does not have the same five year and longer evidence base as oral finasteride.
How Much Finasteride Reaches the Bloodstream?
This is one of the most important differences between topical and oral treatment.
In the large European Phase III study, maximum plasma finasteride concentrations were more than 100 times lower with topical finasteride than with oral finasteride.
At week 24, mean serum DHT had fallen approximately:
34.5 percent with topical finasteride
55.6 percent with oral finasteride
Systemic drug exposure was therefore dramatically lower with the topical spray, but circulating DHT was still meaningfully reduced.
Topical does not mean non systemic.
It means systemic exposure can be substantially reduced when an appropriate formulation and dose are used.
Why Dose and Application Volume Matter
This may be the most misunderstood aspect of topical finasteride.
The percentage printed on a bottle does not tell you the entire dose.
The authorized European spray contains 2.275 mg of finasteride per mL.
Each metered spray delivers approximately 50 microliters containing 114 micrograms of finasteride.
Depending on the treatment area, one to four sprays are used once daily.
That means the actual daily applied finasteride dose ranges from approximately 0.114 mg to 0.456 mg, despite the bottle containing 2.275 mg per mL.
This is why a compounded solution labeled around 0.25 percent cannot automatically be assumed to behave like the Phase III spray.
A patient applying a much larger volume of a similar concentration may expose the scalp and potentially the bloodstream to several times more finasteride.
Concentration and dose are not the same thing.
Does More Topical Finasteride Work Better?
Not necessarily.
Early dose finding research demonstrated that relatively small topical volumes could substantially reduce scalp DHT while producing considerably less suppression of serum DHT.
Daily topical doses using 100 and 200 microliters reduced scalp DHT by approximately 47 and 52 percent while serum DHT fell by approximately 24 and 26 percent.
Increasing the application volume further produced greater suppression of circulating DHT without a consistent corresponding increase in scalp DHT suppression.
This suggests that there can be a point at which additional topical exposure increases systemic biological effect without providing a proportional increase in the desired local effect.
That is why stronger concentrations and larger application volumes should not automatically be assumed to provide better hair results.
What Concentration of Topical Finasteride Is Best?
There is no FDA established topical concentration because topical finasteride is not FDA approved in the United States.
The formulation with the strongest modern Phase III evidence contains 2.275 mg per mL of finasteride, which is close to the concentrations commonly described as approximately 0.25 percent.
But its controlled low application volume is an essential part of the treatment.
American compounded products may use a wide variety of concentrations and application volumes.
Some contain finasteride alone.
Others combine it with minoxidil or additional active ingredients.
When evaluating any topical finasteride prescription, the patient should know:
The concentration
The amount applied with each dose
The number of applications per day
The scalp area being treated
The vehicle
Whether other medications are included
Whether the specific formulation has clinical or pharmacokinetic evidence behind it
A percentage without an application volume is incomplete information.
How Often Should Topical Finasteride Be Applied?
The standardized spray evaluated in the major Phase III program is used once daily.
Earlier experimental studies have evaluated other schedules.
This does not mean every compounded product should automatically be used once daily because formulations and delivered doses differ.
There is no universally established dosing schedule for all compounded topical finasteride preparations in the United States.
Patients should follow the instructions for the specific formulation prescribed.
How Should Topical Finasteride Be Applied?
Application technique matters.
The authorized European spray is applied to a completely dry scalp and dry hair.
The applicator uses a cone designed to help direct the medication onto the scalp rather than allowing most of the product to remain on the hair or disperse into the air.
Depending on the size of the thinning area, one to four separate sprays are applied to nonoverlapping areas.
The goal is to place the medication on the scalp where the follicles are located, not simply coat the hair shafts.
Hands should be washed after application.
These instructions apply to the standardized spray and should not automatically be copied to every compounded foam, gel or solution.
How Long Should Topical Finasteride Stay on the Scalp?
There is not one universal answer for every formulation.
The standardized European spray is instructed to remain on the scalp for at least six hours before washing.
The pivotal clinical trial protocol generally allowed approximately six to eight hours of scalp contact.
The treatment should also be allowed to dry before the treated scalp contacts pillows, hats, helmets or another person.
A compounded formulation may have different instructions.
Patients should follow the application and washing instructions for the exact product being prescribed rather than borrowing the schedule used for another formulation.
How Long Does Topical Finasteride Take to Work?
Topical finasteride should be evaluated over months, not weeks.
The authorized European product information states that approximately three to six months of daily treatment is generally required before signs of hair growth can be expected.
The major Phase III studies used 24 weeks, approximately six months, as the principal efficacy endpoint.
For practical cosmetic assessment, six to twelve months is reasonable.
Standardized photographs and, when available, measurements of hair density and follicular miniaturization are considerably more useful than repeatedly examining the hair under different lighting and styling conditions.
Does Topical Finasteride Have to Be Used Permanently?
For androgenetic alopecia, continued treatment is generally required to maintain treatment dependent benefit.
Topical finasteride does not eliminate the inherited sensitivity of follicles to DHT.
It suppresses part of the miniaturization process while treatment is being used.
If effective treatment is discontinued, androgen driven miniaturization can resume and hair being preserved or supported by treatment can gradually be lost.
Long term discontinuation studies specifically examining topical finasteride are limited, but the underlying biology is the same as with oral finasteride.
Does Topical Finasteride Work on the Hairline?
There is now direct evidence that topical finasteride can benefit areas beyond the crown.
The major randomized trials largely relied on defined vertex target areas because these regions are easier to measure consistently.
However, newer 52 week real world studies measured both the vertex and frontal or temporal regions.
In one 2026 study involving 146 men, target area hair count increased by approximately 32.3 hairs per square centimeter in the frontotemporal region after one year of topical finasteride monotherapy.
Another 52 week study also demonstrated significant improvement in temporal hair measurements.
This strengthens the evidence that topical finasteride can help miniaturizing hair in frontal and temporal regions.
It does not mean that topical finasteride can reliably rebuild deeply recessed temples or recreate a lost juvenile hairline.
Preserving and thickening miniaturized frontal follicles is very different from recreating follicles that no longer produce cosmetically useful hair.
Can Topical Finasteride Cause an Initial Shed?
Some patients report increased shedding after starting topical finasteride.
Unlike minoxidil, however, a predictable initial shedding phase has not been clearly established in large topical finasteride trials.
Temporary changes in shedding may occur as the follicular environment changes, but increased shedding should not automatically be attributed to finasteride.
Persistent or substantial shedding can also reflect progression of androgenetic alopecia, telogen effluvium, illness, nutritional issues, medication changes or another hair disorder.
Does Topical Finasteride Cause Sexual Side Effects?
Potentially, yes.
This is one of the most important questions surrounding topical finasteride.
The purpose of topical treatment is to reduce systemic exposure, but finasteride absorbed through the scalp can still enter the bloodstream and reduce circulating DHT.
In the large Phase III trial, treatment related sexual adverse events were reported in approximately:
2.8 percent of men using topical finasteride
3.3 percent receiving placebo
4.8 percent taking oral finasteride
No participants receiving topical finasteride discontinued treatment because of a treatment related sexual adverse event, compared with some participants receiving oral finasteride.
Sexual function questionnaire results also did not show a significant difference between topical finasteride and placebo.
These findings are reassuring.
However, the trial was not designed or powered to precisely establish the incidence of uncommon sexual adverse effects or prove that topical finasteride produces statistically fewer sexual adverse effects than oral treatment.
The more than 100 fold difference in peak plasma finasteride exposure and the smaller serum DHT reduction provide a strong pharmacologic reason to expect lower systemic exposure.
They do not guarantee that every individual will be free of sexual adverse effects.
The most accurate conclusion is that an appropriately formulated topical finasteride product can substantially reduce systemic exposure and may reduce the likelihood of systemic sexual adverse effects, but it does not eliminate the possibility.
Can Topical Finasteride Cause Persistent Symptoms or Post Finasteride Syndrome?
Persistent symptoms following topical finasteride have been reported.
In 2025, the FDA issued a specific safety alert concerning compounded topical finasteride.
The agency reported 32 adverse event cases between 2019 and 2024 involving compounded topical finasteride alone or in combination with other active ingredients.
Reported symptoms included erectile dysfunction, reduced libido, testicular pain, anxiety, depression, suicidal ideation, cognitive complaints often described as brain fog, fatigue and insomnia.
The FDA stated that most reports described symptoms that continued after the compounded product had been discontinued.
This deserves serious attention.
It does not establish how frequently persistent symptoms occur.
Spontaneous adverse event reports do not provide a controlled denominator of all people using the medication, do not determine incidence and cannot establish that finasteride caused every reported symptom.
The reports also involved different compounded formulations and, in some cases, products containing multiple active ingredients.
The term post finasteride syndrome is used to describe persistent sexual, psychological, cognitive and physical symptoms reported after finasteride exposure. Questions regarding its incidence, mechanisms and whether all reported symptoms represent a single definable syndrome remain unresolved.
The appropriate conclusion is neither that persistent symptoms are impossible nor that they are an expected consequence of topical treatment.
The 2025 FDA Warning About Compounded Topical Finasteride
The FDA warning is particularly important because compounded topical finasteride is now widely marketed through telehealth services and hair loss clinics.
The agency emphasized that:
There is no FDA approved topical finasteride product in the United States.
Systemic absorption through the skin is expected.
Adverse events consistent with systemic finasteride exposure have been reported.
Some consumers reported being told that topical finasteride carried no systemic risk because it was applied to the scalp.
Topical products also create the possibility of unintended exposure to other people, particularly women who are or may become pregnant.
The key consumer message is straightforward:
A topical route of administration should never be marketed as proof that systemic adverse effects cannot occur.
What About Depression and Suicidal Thoughts?
This issue requires a distinction between oral and topical finasteride.
In 2025, the European Medicines Agency completed a broad review of finasteride and dutasteride safety.
EMA concluded that suicidal ideation should be recognized as an adverse effect of oral finasteride tablets.
However, the European review found insufficient evidence to establish a link between suicidal ideation and the authorized finasteride skin sprays.
That is reassuring for the standardized authorized spray formulations.
It should not be interpreted as proof that psychiatric symptoms could never occur with topical finasteride.
The FDA has received psychiatric adverse event reports involving compounded topical products.
These findings are not necessarily contradictory.
European regulators were evaluating standardized authorized topical products, while compounded American products may differ substantially in concentration, application volume, formulation and systemic exposure.
Is Topical Finasteride Safer Than Oral Finasteride?
For a well designed low volume formulation, the available evidence supports substantially lower systemic drug exposure and less serum DHT suppression than oral treatment.
That provides a reasonable biological basis for expecting fewer systemic adverse effects.
The large Phase III study supports that expectation.
Maximum plasma finasteride concentrations were more than 100 times lower with the topical spray, serum DHT suppression was smaller and sexual adverse effects were numerically less frequent.
But the answer becomes more complicated when discussing compounded products.
A higher concentration solution applied in a large volume over a large scalp area may produce substantially greater systemic exposure than the standardized metered spray.
Topical finasteride can reduce systemic exposure. The word topical alone does not guarantee lower systemic exposure.
Why Did Some Earlier Topical Studies Show Large Serum DHT Reductions?
This is another demonstration of why dose and volume matter.
An early pharmacokinetic study used a 0.25 percent topical solution twice daily and found substantially lower plasma finasteride concentrations than oral treatment but similar reductions in circulating DHT.
Serum DHT fell approximately 68 to 75 percent with the topical regimen compared with approximately 62 to 72 percent with oral finasteride.
Later dose finding work showed that smaller topical volumes could retain substantial scalp DHT suppression while reducing serum DHT effects.
The eventual metered spray was developed around this concept.
Lower circulating drug concentration does not necessarily mean minimal systemic biological activity if enough medication is still reaching the bloodstream to suppress serum DHT.
Topical Finasteride Versus Oral Finasteride
Both treatments contain the same active medication and inhibit the same enzyme.
The principal difference is how the drug is delivered and how much reaches the systemic circulation.
Oral finasteride provides predictable systemic dosing and has the deeper long term evidence base.
Topical finasteride attempts to produce sufficient scalp exposure with less systemic drug exposure.
A standardized topical formulation has demonstrated short term efficacy numerically similar to oral finasteride with dramatically lower peak plasma finasteride concentrations and less suppression of circulating DHT.
Which approach is appropriate depends on the individual patient’s treatment response, concerns, tolerance and long term strategy.
A patient doing extremely well on oral finasteride without adverse effects should not assume that he needs to switch simply because topical therapy is available.
Likewise, a patient unwilling or unable to take oral finasteride may reasonably discuss topical treatment with his physician.
Can Topical Finasteride Be Used With Oral Finasteride?
It can be prescribed that way, but routine combination therapy has not been adequately established in controlled trials.
Both treatments deliver the same active medication.
Adding topical finasteride to oral finasteride may increase follicular exposure and total drug exposure, but strong evidence demonstrating that routinely combining the two produces enough additional benefit to justify the added treatment is lacking.
More finasteride is not automatically better.
Someone already responding well to oral finasteride should have a clear reason for adding topical finasteride rather than simply pursuing greater DHT suppression.
Topical Finasteride With Minoxidil
Topical finasteride is frequently combined with topical minoxidil.
The medications perform different functions.
Finasteride addresses DHT driven follicular miniaturization.
Minoxidil primarily acts as a growth stimulant.
Several randomized studies have found that topical finasteride combined with minoxidil can produce greater average improvement than minoxidil alone, and some comparative studies suggest greater improvement than either topical medication used by itself.
Combination treatment is therefore biologically and clinically reasonable.
It is not automatically necessary for every patient.
Are Combination Products Better Than Using the Medications Separately?
Not necessarily.
A fixed combination can be convenient and may improve adherence by allowing a patient to apply both medications at once.
But combination products also reduce flexibility.
If irritation, shedding or another adverse effect develops, it can be more difficult to determine which medication or vehicle is responsible.
The dose of one active ingredient also cannot easily be changed without changing the other.
A patient who needs less finasteride but wants to continue the same amount of minoxidil may be easier to manage with separate formulations.
Convenience and treatment flexibility are different considerations.
What About Topical Finasteride Plus Oral Minoxidil?
This combination is increasingly prescribed through hair loss practices and telehealth services.
The medications act through different mechanisms and may be complementary.
But each medication still needs to be evaluated independently.
Using oral minoxidil does not make the systemic exposure from topical finasteride irrelevant.
Likewise, using topical finasteride does not remove the cardiovascular considerations associated with oral minoxidil.
A multi drug regimen should have a clear treatment rationale rather than simply including every medication available.
Can Topical Finasteride Irritate the Scalp?
Yes.
Topical finasteride can cause itching, redness, burning, dryness, scaling or irritation.
The active medication is not always responsible.
Alcohol, propylene glycol, preservatives and other components of the vehicle can affect tolerability.
The major Phase III trials generally found low rates of clinically significant scalp reactions.
The newer one year observational studies reported mild temporary local irritation in approximately 6 to 7 percent of patients.
Someone who reacts to one formulation may tolerate a different vehicle.
Does Microneedling Change Topical Finasteride Absorption?
Potentially, yes.
Microneedling intentionally disrupts the skin barrier.
That can increase penetration of substances applied afterward.
For topical finasteride, one of the primary goals is often to balance follicular delivery against systemic absorption.
Applying a topical finasteride preparation to freshly microneedled skin can alter that balance.
A product designed and dosed for intact scalp skin should not automatically be assumed to have the same pharmacokinetics when applied through newly created channels.
More penetration is not necessarily better when one purpose of topical therapy is to limit systemic exposure.
Using microneedling specifically to enhance prescription finasteride delivery should be medically directed.
Can Topical Finasteride Transfer to Another Person?
Yes.
This is a legitimate consideration.
Unlike an intact coated tablet, topical finasteride is placed directly onto the skin.
Medication remaining on the fingers, treated scalp, hair, pillowcase, hat or another surface can potentially be transferred before it has dried or been washed away.
The FDA specifically warned about unintended exposure from compounded topical finasteride, particularly exposure involving women who are or may become pregnant.
Authorized European product instructions likewise advise allowing the spray to dry and avoiding contact between the treated scalp and surfaces or other people while the product remains wet.
Topical Finasteride and Pregnancy
Finasteride can interfere with normal development of the external genitalia of a male fetus.
Pregnancy exposure is therefore an important safety concern.
Women who are pregnant or may become pregnant should avoid exposure to topical finasteride.
Topical products deserve particular caution because the active medication is deliberately exposed on the skin rather than sealed inside an intact coated tablet.
Patients should wash their hands after application and follow the transfer precautions associated with the exact formulation.
Can Women Use Topical Finasteride for Hair Loss?
Topical finasteride has been studied in women, but the evidence is substantially less developed than it is in men.
One randomized controlled study involving 30 postmenopausal women compared topical finasteride 0.25 percent combined with minoxidil 3 percent against minoxidil alone for 24 weeks.
Both groups improved, but the finasteride and minoxidil combination produced a significantly greater improvement in hair diameter.
Importantly, serum DHT also decreased significantly in the topical finasteride group, demonstrating that systemic absorption occurred even in this topical treatment study.
Additional small observational and comparative studies have continued to explore topical finasteride in women.
However, there are no large Phase III female pattern hair loss trials comparable to those performed in men.
Reproductive risk also remains a major limitation.
Topical finasteride should not be presented to women as a purely localized treatment without potential systemic or reproductive implications.
Use in women remains off label and requires careful patient selection.
Can Topical Finasteride Affect Fertility?
This has not been adequately established.
Oral finasteride has been associated with changes in semen parameters in some susceptible men, although controlled studies of healthy men have generally been reassuring.
Lower systemic exposure from a well designed topical formulation provides a reasonable basis for expecting less systemic reproductive effect.
But that is not the same as proving no effect.
The major Phase III topical finasteride trial excluded men with a history of infertility or difficulty fathering children.
The pivotal trial therefore was not designed to establish fertility safety specifically in men who already have reproductive problems.
Because compounded topical formulations can also produce very different systemic exposures, there is not enough evidence to state that topical finasteride has no potential effect on male fertility.
Men with known fertility problems or those actively attempting conception should discuss this with their physician.
Can Topical Finasteride Affect PSA?
Oral finasteride lowers prostate specific antigen, or PSA.
Whether topical finasteride meaningfully affects PSA depends on systemic exposure and the amount of circulating DHT suppression.
The standardized topical spray produces less serum DHT suppression than oral finasteride, but serum DHT is still reduced.
Long term PSA data for topical finasteride remain limited.
A man using topical finasteride should therefore tell the physician responsible for interpreting his PSA, particularly when he is using a compounded formulation whose systemic exposure has not been characterized.
What About Blood Donation?
Blood donation organizations restrict finasteride exposure because donated blood could potentially be given to a pregnant recipient.
The American Red Cross currently requires people taking Propecia or Proscar to wait one month after their last dosebefore donating blood.
It does not publish a separate explicit rule covering every compounded topical finasteride formulation.
Because topical finasteride can be systemically absorbed and compounded products vary, a patient should disclose topical finasteride use to the blood donation organization and follow that organization’s eligibility determination rather than assuming topical administration eliminates the restriction.
Should Someone Switch From Oral Finasteride to Topical Finasteride?
Not automatically.
Someone who has maintained his hair successfully for years on oral finasteride with acceptable tolerability already has a treatment strategy that is working.
Changing a successful regimen introduces uncertainty.
Topical finasteride may be particularly appealing for men who do not want to take oral finasteride, have experienced adverse effects with oral treatment, want to reduce systemic exposure or have another physician directed reason for choosing a topical route.
But topical treatment should not automatically be described as superior or completely safe simply because it is topical.
Treatment escalation or switching should have a reason.
What Should Someone Ask Before Using Compounded Topical Finasteride?
A patient should know exactly what is being prescribed.
Important questions include:
What concentration of finasteride does the product contain?
How much solution, foam or gel is applied with each dose?
How many times each day is it applied?
How large an area of scalp is being treated?
What vehicle is being used?
Is minoxidil or another active medication included?
Was this exact formulation studied clinically?
Is there pharmacokinetic information showing how much finasteride reaches the bloodstream?
How much does the formulation reduce serum DHT?
How long should the product remain on the scalp?
What precautions are necessary around women who are or may become pregnant?
What should be done if sexual, psychological or other systemic symptoms occur?
The word topical does not answer these questions.
The AHLA Perspective
Topical finasteride has moved well beyond being merely an experimental idea.
A standardized topical finasteride spray has demonstrated meaningful efficacy in multiple Phase III trials and has been authorized for male androgenetic alopecia in a number of European countries.
The strongest modern randomized trial found hair count improvement numerically similar to oral finasteride over 24 weeks while producing more than 100 times lower peak plasma finasteride concentrations and substantially less suppression of serum DHT.
Newer 52 week real world studies have also demonstrated continued improvement in the vertex and frontal or temporal scalp, adding useful longer term evidence.
These developments are significant.
They establish that local scalp treatment can provide meaningful finasteride activity while reducing systemic drug exposure.
But topical finasteride should not be oversold.
There is still no FDA approved topical finasteride product in the United States. American compounded formulations can vary considerably in concentration, vehicle, dose and application volume.
The pharmacokinetic and safety profile of a carefully engineered metered low volume spray cannot automatically be assigned to every compounded product marketed as topical finasteride.
The 2025 FDA warning reinforces this point. Sexual, psychiatric and other systemic symptoms have been reported with compounded topical products, and most of the submitted reports described symptoms continuing after treatment was stopped. Those reports deserve attention, but spontaneous adverse event reports cannot establish incidence or prove causation in every individual.
At the same time, the European regulatory review found insufficient evidence to establish a relationship between suicidal ideation and the standardized authorized finasteride skin sprays.
Both pieces of information belong in an informed discussion.
Topical finasteride can substantially reduce systemic exposure. It does not eliminate systemic exposure.
For appropriately diagnosed men who want to treat androgenetic alopecia while limiting systemic finasteride exposure, an appropriately formulated topical treatment can be a legitimate and potentially valuable option.
The decision between oral and topical therapy should not be driven by fear, marketing or the assumption that one route is automatically superior.
The objective is to identify the lowest effective and sustainable exposure that provides adequate long term control of follicular miniaturization with acceptable tolerability for the individual patient.
Used for: Male Pattern Baldness
Selected References
- Piraccini BM, Blume Peytavi U, Scarci F, et al. Efficacy and Safety of Topical Finasteride Spray Solution for Male Androgenetic Alopecia: A Phase III Randomized Controlled Clinical Trial. Journal of the European Academy of Dermatology and Venereology. 2022;36:286 to 294. doi:10.1111/jdv.17738. PubMed
- Zhou C, Yang B, Zeng H, et al. Efficacy and Safety of Topical Finasteride Spray Solution in the Treatment of Chinese Men With Androgenetic Alopecia: A Phase III, Multicenter, Randomized, Double Blind, Placebo Controlled Study. Chinese Medical Journal. 2026;139:1054 to 1061. doi:10.1097/CM9.0000000000003495. PubMed
- Gallo G, Mastorino L, Quaglino P, Ribero S. Long Term Effectiveness and Safety of Topical Finasteride 0.25 Percent Monotherapy in Male Androgenetic Alopecia: A 52 Week Real World Retrospective Study. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag333. PubMed
- Piraccini BM, Rapparini L, Quadrelli F, et al. Effectiveness and Safety of Topical Finasteride for Male Androgenetic Alopecia: Real World Data. International Journal of Dermatology. 2026;65:2102 to 2107. doi:10.1111/ijd.70394. PubMed
- Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A Novel Finasteride 0.25 Percent Topical Solution for Androgenetic Alopecia: Pharmacokinetics and Effects on Plasma Androgen Levels in Healthy Male Volunteers. International Journal of Clinical Pharmacology and Therapeutics. 2014;52:842 to 849. doi:10.5414/CP202119. PubMed
- Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a Novel Finasteride 0.25 Percent Topical Solution on Scalp and Serum Dihydrotestosterone in Men With Androgenetic Alopecia.International Journal of Clinical Pharmacology and Therapeutics. 2016;54:19 to 27. doi:10.5414/CP202467. PubMed
- Arsal SA, Kumar A, Iqbal U, et al. Comparison of Topical Finasteride and Oral Finasteride in the Treatment of Androgenetic Alopecia: A Systematic Review and Meta Analysis. American Journal of Therapeutics. 2025. PubMed
- Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of Topical Combination of 0.25 Percent Finasteride and 3 Percent Minoxidil Versus 3 Percent Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double Blind, Controlled Study. American Journal of Clinical Dermatology. 2019;20:147 to 153. doi:10.1007/s40257-018-0387-0. PubMed
- Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A Randomized Double Blind Controlled Study of Topical Finasteride Combined With Minoxidil Compared With Minoxidil Alone in Male Androgenetic Alopecia. PubMed
- Rossi A, Caro G. Comparative Efficacy of Topical Finasteride in Combination With Minoxidil Against Minoxidil or Finasteride Alone in Male Androgenetic Alopecia. PubMed
- U.S. Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Consumers of Potential Risks Associated With Compounded Topical Finasteride Products. 2025. FDA Safety Alert
- European Medicines Agency. Finasteride and Dutasteride Containing Medicinal Products: European Safety Review. 2025. EMA Safety Review
- European Medicines Agency. List of Authorized Finasteride Products Including 2.275 mg per mL Cutaneous Finasteride Sprays. EMA Authorized Products
- Fynzur 2.275 mg per mL Finasteride Cutaneous Spray: Patient Information and Application Instructions.Includes one to four daily sprays, dry scalp application, six hour minimum contact time and transfer precautions. Authorized Product Information
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA Compounding Information
- American Red Cross. Blood Donor Eligibility Criteria: Finasteride and Other Medications. American Red Cross Eligibility Information